You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Paragraph IV Challenges


✉ Email this page to a colleague

« Back to Dashboard


Tradename Dosage Generic Name NDA ANDAs Submitted 180 Day Exclusivity Status Submissiondate
REYVOW Tablets lasmiditan succinate 211280 1 2024-01-31
MYRBETRIQ GRANULES Granules for Extended-release Suspension mirabegron 213801 1 2024-01-12
ATROVENT HFA Inhalation Aerosol ipratropium bromide 021527 1 2023-12-29
>Tradename >Dosage >Generic Name >NDA >180 Day Exclusivity Status >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.